Demo: CRISPR IP drift posture report
A single-page posture report generated deterministically from Evidence Packets: baseline → delta → actionable queues.
This is in silico sequence monitoring. It is not legal advice and not an infringement/FTO conclusion.
Browse the PatentChecker demo set
Jump between live posture reports, delivery blocking analysis, and offline-verifiable proof bundles without backing out to the PatentChecker overview.
Vector blocking analysis across capsid overlap, licensing dependency, manufacturing sensitivity, and exclusivity zones.
Live posture report for sequence-watchlist drift: baseline, delta, open actions, and monitoring queues.
Downloadable drift packet with checksums, manifest verification, and contract-validated Evidence Packet JSON.
Verifiable runner-image quickstart for the signed PatentChecker evaluation path.
Replay-verifiable PTAB evidence bundle with decision metadata, captures, provenance, and verifier scripts.
Signed deterministic proof bundle for an engineering and procurement review workflow.
Report header
- Match indicates similarity under configured method
- Outputs are informational; not legal advice
- Not an infringement or Freedom-to-Operate (FTO) determination
- Claim scope review required before action
Current posture (one page)
Rows are stably ordered by family_id. Fresh-look triggers are explicit enums to avoid ambiguity.
| Family | Severity | Owner | What changed | Why it matters | Recommended action |
|---|---|---|---|---|---|
| US-CRISPR-FAM-001 | HIGH | Broad Institute, Inc. competitor watch | new_publicationroi_overlap_delta new_publication(US2024000100); roi_overlap_delta(0.63→0.40) | High-similarity competitor family with fresh-look triggers; prioritize claim scope review. | Triage ticket: counsel + R&D (claim scope + design-around). |
| US-CRISPR-FAM-002 | MEDIUM | University of California; University of Vienna competitor watch | no material delta | No material delta detected; keep under watch. | Monitor: no material delta. |
| US-CRISPR-FAM-003 | HIGH | Editas Medicine, Inc. portfolio watch | new_publicationnew_family_detected new_publication(US2023000300); new_family_detected(HIGH,id=0.91,qcov=0.82) | Internal portfolio activity detected for governance/annotation (not an external risk conclusion). | Portfolio watch: annotate as internal activity; route to portfolio owner. |
| US-CRISPR-FAM-004 | MEDIUM | Intellia Therapeutics, Inc. competitor watch | new_publicationnew_family_detected new_publication(US2024000456); new_family_detected(MEDIUM,id=0.84,qcov=0.65) | Competitor posture changed in a counsel-relevant way (publication or band/family change). | Counsel review: assess claim scope and program relevance. |
Download and verify
Download the full CRISPR IP drift demo bundle (inputs, engine outputs, run artifacts, and report) to rerun or inspect offline.
Queues
- US-CRISPR-FAM-001 — Triage ticket: counsel + R&D (claim scope + design-around).
- US-CRISPR-FAM-004 — Counsel review: assess claim scope and program relevance.
- US-CRISPR-FAM-002 — Monitor: no material delta.
- US-CRISPR-FAM-003 — Portfolio watch: annotate as internal activity; route to portfolio owner.